Selling, General, and Administrative Costs: Amgen Inc. vs Viridian Therapeutics, Inc.

A Tale of Two Companies: Amgen Inc. vs. Viridian Therapeutics, Inc.

In the ever-evolving pharmaceutical landscape, understanding the financial dynamics of industry giants and emerging players is crucial. Amgen Inc., a stalwart in biotechnology, has consistently demonstrated robust financial health. From 2014 to 2023, Amgen's Selling, General, and Administrative (SG&A) expenses have shown a steady increase, peaking at approximately $6.2 billion in 2023, marking a 31% rise over the decade.

In contrast, Viridian Therapeutics, Inc., a burgeoning entity in the therapeutic space, has seen its SG&A expenses grow exponentially, from a modest $7.8 million in 2014 to nearly $95 million in 2023. This represents a staggering 1,120% increase, reflecting its aggressive expansion and investment in growth.

This comparison highlights the contrasting strategies of established and emerging companies in managing operational costs, offering valuable insights into their financial trajectories and market positioning.